Login / Signup
Population Pharmacokinetic Analysis of the RNAi Therapeutic Givosiran in Patients with Acute Hepatic Porphyria.
Megan Melch
Jongtae Lee
Claudia Jomphe
Gabriel J Robbie
Published in:
Clinical pharmacokinetics (2023)
The PK of givosiran and its active metabolite were not significantly affected by demographic or clinical parameters that would require adjustment from the approved body weight-based dose of givosiran 2.5 mg/kg once monthly.
Keyphrases
</>
body weight
drug administration